Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with UFT in Japan

T Taguchi1

  • 1Osaka University, Japan.

Oncology (Williston Park, N.Y.)
|February 12, 1998
PubMed
Summary
This summary is machine-generated.

Tegafur and uracil (UFT) enhances fluorouracil in tumors, offering clinical benefits and lower toxicity. This combination chemotherapy shows promise for various cancers, including head/neck, bladder, and breast.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The effect of CPT-11 in combination with interferon-alpha against human colon carcinoma heterotransplanted in nude mice: preliminary report].

Nihon Geka Gakkai zasshi·1992
Same author

[Correlation of DBA lectin binding and malignancy in breast cancers: preliminary report].

Nihon Geka Gakkai zasshi·1992
Same author

Pokeweed mitogen induces p55 interleukin-2 receptor expression on human monocytes and its effect on interleukin-2 activated monocyte cytotoxicity.

Immunological investigations·1992
Same author

[Athyreotic congenital hypothyroidism in two sisters].

Nihon Naibunpi Gakkai zasshi·1992
Same author

Immunological identification of a Cl- channel protein in electric organs of Narke japonica.

Biochemical and biophysical research communications·1992
Same author

DNA synthesis and related enzymes altered in compensatory lung growth in rats.

Scandinavian journal of clinical and laboratory investigation·1992
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Therapeutics

Background:

  • Tegafur and uracil (UFT) demonstrates selective antineoplastic effects by increasing fluorouracil concentration in tumor tissues.
  • This mechanism leads to improved clinical benefits and reduced toxicity compared to other fluorinated pyrimidines.
  • Extensive preclinical and clinical research in Japan since the 1980s has established UFT's therapeutic advantages.

Purpose of the Study:

  • To review the therapeutic advantages and clinical applications of tegafur and uracil (UFT) in cancer treatment.
  • To summarize findings from various clinical trials, including dose-finding, multicenter, comparative, and combination chemotherapy studies.
  • To evaluate UFT's efficacy and safety profile in diverse oncological settings.

Main Methods:

Related Experiment Videos

  • Review of preclinical studies and numerous Japanese clinical trials (Phase I, II, comparative, combination chemotherapy).
  • Analysis of data from 211 institutions regarding response rates and survival in head/neck, bladder, and breast cancer.
  • Comparison of UFT efficacy against single-agent tegafur and assessment of combination therapy outcomes.

    • Main Results:

    • Phase II studies reported over 30% response rates in head/neck, bladder, and breast cancers, with superior survival rates compared to historical Japanese data.
    • Comparative studies indicated UFT's greater effectiveness than single-agent tegafur.
    • Combination chemotherapy studies highlighted advantages in toxicity, response, and survival rates.

    Conclusions:

    • Tegafur and uracil (UFT) offers significant therapeutic advantages, including enhanced efficacy and reduced toxicity in various cancers.
    • UFT is effective for both advanced disease and postoperative adjuvant therapy across multiple neoplasms.
    • Further trials are warranted to refine and confirm UFT's role in comprehensive cancer treatment strategies.